glp-1 receptor agonists cardiovascular benefits The Biology of Glucagon-like Peptide-1 Discover the Game-Changing Benefits of
Description
Liraglutide treatment in a patient with HIV, type 2 diabetes and sleep apnoea-hypopnoea syndrome
The first draft of the manuscript was written by [Juliana Giorgi], improved by [Mrunalini Dandamudi], and reviewed by [Alejandro Barbagelata] and [Edgardo Kaplinsky]
Evidence for Cardiovascular Safety The DPP-4 inhibitors have not demonstrated any sustained or clinically significant reduction in other cardiovascular risk factors, such as blood pressure or lipids
Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretion
GLP-1 in patients with myocardial infarction complicated by cardiogenic shockan IABP-SHOCK II-substudy
Sports 35 , 318319 (2020)
